ClinicalTrials.gg
Not yet recruitingNCT07861126RESTORE-TBIUpdated Oct 13, 2026

Sovateltide for the Treatment of Acute Traumatic Brain Injury

A Phase 3 interventional study of Placebo and Sovateltide in Traumatic Brain Injury, sponsored by Pharmazz, Inc.. Not yet recruiting. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Pharmazz, Inc. · Phase 3, Interventional, and Treatment

Updated Oct 13, 2026Primary outcomes revisedTitle changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Traumatic brain injury (TBI) remains a leading cause of global disability, yet current clinical management is limited to supportive care and pressure stabilization using hyperosmolar therapies like mannitol and hypertonic saline. These strategies fail to address the destructive cellular cascades that persist long after the initial impact, leaving 66.3% of severe TBI patients with permanent cognitive and neurological deficits. To bridge this critical unmet medical need, the therapeutic focus must shift toward neuroprotective and neuroregenerative agents that actively block secondary injury cascades such as excitotoxicity, apoptosis, and chronic neuroinflammation.

Sovateltide is a selective endothelin-B receptor agonist. It was previously reported to reduce apoptosis, stimulate neurogenesis, and improve functional recovery. Unlike most TBI candidates restricted to preclinical phases, sovateltide possesses a robust human safety and tolerability profile established across Phase I, II, III, and IV ischemic stroke trials.

We conducted a preclinical study in Wistar rats with induced TBI and showed that sovateltide effectively preserved BBB integrity, a critical determinant of post-injury outcomes, and significantly reduced neuronal apoptosis, as evidenced by decreased expression of caspase-3 and caspase-6, key markers of programmed cell death. Treated animals also exhibited notable improvements in neurobehavioral performance, reflecting functional recovery likely attributable to the drug's antioxidant, anti-inflammatory, and anti-apoptotic mechanisms. These results align with earlier evidence showing that ETB receptor activation enhances angiogenesis, neurogenesis, and synaptic remodeling, processes essential for neural repair following brain injury.

The present study has been designed to advance sovateltide (IRL-1620) into a pivotal Phase III clinical trial for acute traumatic brain injury (TBI). With millions affected annually and zero approved neuroprotective pharmacotherapies available, this milestone marks a critical step forward in addressing one of modern medicine's greatest unmet needs. By harnessing our proprietary neural repair discovery platform, sovateltide targets the cascade of secondary cell death while stimulating neurogenesis and angiogenesis. Building on the strong momentum of our ongoing global Phase III RESPECT-ETB study in acute ischemic stroke, this study will further validate the broad therapeutic potential of our endothelin-B receptor platform across severe acute neurovascular conditions.

Read the detailed description

A traumatic brain injury (TBI) is a form of brain damage that results from an external mechanical force impacting the head or body, such as a sudden blow, jolt, or wound. The injuries could be penetrating (open) ones - commonly seen in motor vehicle accidents, falls, sports injuries, and explosive blasts in which an object such as a bullet, shrapnel, or bone fragment breaches the skull and directly damages brain tissue, or non-penetrating (closed or blunt) ones, which result from rapid acceleration, deceleration, or rotational forces that cause the brain to move within the skull. Based on the timing of the impact and damage, these injuries are categorized as primary or secondary. Primary injuries, such as contusions, lacerations, or hemorrhage, occur at the moment of impact and involve immediate damage. Secondary injury develops over time through complex biochemical and physiological processes such as increased intracranial pressure, cerebral edema, ischemia, excitotoxicity, oxidative stress, and neuroinflammation, which can worsen neurological outcomes later.

According to the Global Burden of Diseases database in 2021, there were 20.84 million incident cases and 37.93 million prevalent cases of TBI worldwide. Between 1990 and 2021, the global number of TBI incidents and prevalent cases increased by 22.6% and 53.3%, respectively; however, the age-standardized incidence rate declined by 0.11%. These rates generally increased with age and were higher in males than in females. The highest age-standardized prevalence and years lived with disability rates were observed in Eastern and Central Europe. Globally, falls were the leading cause of TBI in 2021, followed by road injuries, violence, and exposure to mechanical forces.

Currently, no therapeutic agent is approved for TBI because of the injury's biological complexity, heterogeneity in patient presentation, and limited translation of preclinical success into human trials. Hence, future progress likely depends on developing drugs or combination therapies with multimodal mechanisms of action that support neural cell protection, regeneration, repair, and functional restoration. Moreover, TBI pathophysiology is complex, involving vascular damage, inflammation, apoptosis, and other processes that trigger neuronal damage and death. A thorough understanding of TBI pathophysiology is essential for developing novel therapeutic agents that provide neuroprotection by curbing inflammation, enhancing angiogenesis, reducing hypoxic episodes, excitotoxicity, and apoptosis, and promoting neuroregeneration in injured brain tissue. Endothelin signaling regulates these pathophysiological events in the mammalian neurovascular system; therefore, the endothelin system could be a potent drug-development target in TBI.

Sovateltide (TycamzziTM, IRL-1620, PMZ-1620) is a first-in-class ETB receptor agonist approved in India for treating acute ischemic stroke (AIS), promoting neuroprotection and regeneration via neuron and blood vessel growth. We evaluated the neuroprotective potential of sovateltide in the Marmarou weight-drop rat model of traumatic brain injury (TBI). TBI onset in rats damaged blood-brain barrier (BBB) and increased brain water content, inflammation and oxidative stress. Neuronal damage in the prefrontal cortex and hippocampal subfields (CA1-CA3 and dentate gyrus) was seen on day 1 post-injury. A marked increase in Neurobehavioral Severity Score-Revised (NSS-R), indicating neurological impairment, was also observed. Rats were either treated with sovateltide (5μg/kg) or mannitol (20% w/v) or Normal Saline (5ml/kg) administered three times a day on 1st, 3rd and 6th day after induction of TBI. Animals treated with sovateltide or mannitol showed progressive functional recovery with a significantly reduced NSS-R score compared to untreated TBI rats by day 7. These animals also showed a clear trend toward behavioral improvement; however, anxiety levels and locomotor activity remained comparable. Damage to the BBB, reflected by elevated Evans Blue Dye elution, was substantially reduced in sovateltide-treated rats. Sovateltide exhibited antioxidant activities and reduced malondialdehyde (MDA) levels, restoring superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH) levels to near-normal. Sovateltide-treated rats had decreased inflammatory indicators/mediators (e.g., NF-κB, IL-6, and TNF-α) compared with untreated and mannitol-treated animals. At the tissue level, sovateltide-treated animals had better-preserved neural tissue architecture, like sham animals, than control and mannitol-treated animals. Apoptotic markers caspase-3 and caspase-6 were significantly reduced in sovateltide animals, along with attenuation of astrocytic activation indicated by decreased GFAP in cortical and hippocampal regions. Thus, sovateltide confers multimodal neuroprotection by alleviating oxidative stress, suppressing neuroinflammation, preserving BBB integrity and neuronal morphology, and inhibiting apoptosis following TBI.

A TBI study in Wistar rats found that sovateltide preserved BBB integrity and reduced apoptosis, as evidenced by decreased caspase-3 and caspase-6 expression and improved neurobehavioral outcomes, likely due to its antioxidant and anti-apoptotic properties. Overall, studies show that the endothelin system, particularly ETB receptor signaling, represents a promising therapeutic axis that can address TBI heterogeneity by integrating vascular protection, anti-inflammatory effects, and neural regeneration. Unlike traditional monotherapies that target isolated pathways, ETB activation through sovateltide would offer a multimodal approach to target the full spectrum of TBI, from acute neuroprotection to long-term neural repair.

  • Sovateltide stimulates ETB receptors, which are highly expressed during neural development. Research indicates that activating these receptors in the adult brain enhances NPC proliferation and differentiation into mature, functional neurons.
  • Effective neurogenesis requires a robust blood supply. Sovateltide promotes the formation of new micro-vessels (angiogenesis) by increasing levels of Vascular Endothelial Growth Factor (VEGF) and Nerve Growth Factor (NGF). This ensures that the "new" brain tissue has the oxygen and nutrient support needed to survive and integrate.
  • Sovateltide has been shown to inhibit the pathways that lead to delayed neuronal death. Protecting existing neurons in the "penumbra" (the area surrounding the core injury) limits the eventual size of the brain lesion.
  • Research suggests that Sovateltide enhances mitochondrial biogenesis and maintains mitochondrial membrane potential. Since TBI causes massive metabolic failure, stabilizing the cell's "powerhouse" is critical for preventing further tissue loss.
  • Stimulation of ETB receptors on the vascular endothelium triggers the release of nitric oxide, leading to vasodilation and improved perfusion to the injured regions.

The pathophysiological similarities between stroke and TBI-specifically the roles of ischemia, inflammation, and the need for remodeling-provide a strong "proof of concept" for the application of sovateltide in TBI.

02

Conditions studied

  • Traumatic Brain Injury

Keywords

  • Traumatic Brain Injury
  • TBI (Traumatic Brain Injury)
  • Brain Injuries, Traumatic
03

In context

Brain Injuries, Traumatic

1,722 studies on the registry are indexed under Brain Injuries, Traumatic; 448 are open to participants now.

This study's planned enrollment of 214 is above the median of 52 across 1,089 interventional studies indexed under Brain Injuries, Traumatic.

Browse Brain Injuries, Traumatic studies →

Lead sponsor

Pharmazz, Inc. is the lead sponsor of 14 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A participant will be eligible for inclusion in the study if the participant fulfills the following criteria:

  1. Adult male or female aged 18-90 years
  2. Consent must be obtained prior to any study-specific procedure from the participant or, if the participant lacks capacity to provide , from the participant's Legally Authorized Representative (LAR), in accordance with applicable law and IRB requirements.
  3. Clinical diagnosis of closed traumatic brain injury (TBI), classified as moderate to severe, with a post-resuscitation Glasgow Coma Scale (GCS) score of 5 to 13, inclusive, at screening (moderate TBI: GCS 9-13; eligible severe TBI range: GCS 5-8).
  4. Radiological confirmation of TBI on neuroimaging (diffuse injury II-V, Marshall's CT Classification).
  5. At least one reactive pupil (pinpoint pupils due to opioid pain treatment are considered reactive).
  6. The participant is \<48 hours from the time of TBI onset when the first dose of sovateltide is administered. The time of TBI onset is when the injury occurred.
  7. Reasonable expectation of availability to receive the full sovateltide course of therapy and to be available for subsequent follow-up visits.

Exclusion criteria

Exclusion Criteria:

A participant will not be considered eligible for inclusion in this study if the participant meets any of the following exclusion criteria:

  1. TBI caused by penetrating injury (e.g., gunshot wound) rather than blunt trauma.
  2. Isolated epidural hematoma.
  3. Suspected or confirmed spinal cord injury.
  4. Severe cardiac or hemodynamic instability prior to randomization.
  5. of less than 72 hours as determined by the Investigator.
  6. Pregnant or lactating women.
  7. Known medical history of neurological (other than current TBI) or psychiatric condition that, in the investigator's opinion, would confound the neurological and functional evaluations, lead to further deterioration of neurological status, or interfere with participation in this study.
  8. Evidence of any other major life-threatening or serious medical condition, such as severe renal, hepatic, and cardiovascular disease, which would prevent completion of the study protocol, impair the assessment of outcome, or in which sovateltide therapy would be or might cause harm to the participant.
  9. Concurrent participation in any other therapeutic clinical trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
214 participants (estimated)

Study arms

  • Placebo comparator
    The reference product is a matching placebo for sovateltide

    Drug: Placebo

  • Active comparator
    The test product is sovateltide

    Drug: Sovateltide

Interventions

  • DrugPlacebo

    The reference product is a matching placebo for sovateltide. It is a sterile lyophilized injection consisting of excipients formulated without the active ingredient in a 5.0 mL vial, to be reconstituted in 5 mL of normal saline (0.9% Sodium Chloride Injection).

  • The test product is sovateltide. It is available as a lyophilized injection containing 30 μg of sovateltide in a 5.0 mL vial, to be reconstituted in 5 mL normal saline (0.9% Sodium Chloride Injection).

    Also known as: IRL-1620

06

What researchers measure

Primary outcomes

  1. Proportion of patients achieving a favorable functional outcome (GOS-E score ≥7) at Day 90 post-randomization. Score range: 1 to 8; higher scores represent a better outcome.

    Score Range: 1 to 8 (minimum: 1, maximum: 8); Direction of Score: Higher scores represent a better outcome (1 indicates Death; 7 indicates Lower Good Recovery; 8 indicates Upper Good Recovery).

    Time frame: 90 days

Secondary outcomes

  1. Proportion of patients achieving a favorable functional outcome (GOS-E score ≥7) at Day 180 post-randomization. Score range: 1 to 8; higher scores represent a better outcome.

    Score Range: 1 to 8 (minimum: 1, maximum: 8); Direction of Score: Higher scores represent a better outcome (1 indicates Death; 7 indicates Lower Good Recovery; 8 indicates Upper Good Recovery).

    Time frame: 180 days

  2. Proportion of patients achieving a favorable functional outcome (GOS-E score ≥7) at Day 30 post-randomization. Score range: 1 to 8; higher scores represent a better outcome.

    Score Range: 1 to 8 (minimum: 1, maximum: 8); Direction of Score: Higher scores represent a better outcome (1 indicates Death; 7 indicates Lower Good Recovery; 8 indicates Upper Good Recovery).

    Time frame: 30 days

  3. Proportion of patients with an improvement in Disability Rating Scale (DRS) to less than or equal to 3 at Days 30, 90, and 180 post randomization. Score range: 0 to 30; higher scores represent a worse outcome.

    Score Range: 0 to 30 (minimum: 0, maximum: 30); Direction of Score: Higher scores represent a worse outcome (0 indicates no disability; 30 indicates death).

    Time frame: 180 days

  4. Change in the Montreal Cognitive Assessment (MoCA) at Days 30, 90, and 180 post-randomization. Score range: 0 to 30; higher scores represent a better outcome.

    Score Range: 0 to 30 (minimum: 0, maximum: 30); Direction of Score: Higher scores represent a better outcome (scores of 26 and above are generally considered normal cognitive function; lower scores indicate greater cognitive impairment).

    Time frame: 180 days

  5. Change in the quality-of-life outcomes using Short Form (36) Health Survey (SF-36) at Days 30, 60, 90, 135, and 180 post-randomization.

    Time frame: 180 days

  6. Hospital free days from randomization to Day 90.

    Time frame: 90 days

  7. ICU free days from randomization to Day 90.

    Time frame: 90 days

  8. Incidence of all-cause mortality from randomization to Day 180.

    Time frame: 180 days

  9. Proportion of patients with adverse events (AEs) and serious adverse events (SAEs).

    Time frame: 180 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Davenport A, Anwar M, Kuc R, Brynne L, Mercier A, Astrand M, Greasley P, Ambery P, Maguire J. Next-generation therapeutics and renaissance of legacy drugs targeting the endothelin system. Can J Physiol Pharmacol. 2026 Jan 1;104:1-16. doi: 10.1139/cjpp-2026-0068. PubMed 42378327 ↗
  • Kandasamy G, Selvaraj L, Orayj K, Almanasef M, Hmlan A, Asiri R, Aldahish AA, Mani V, Saravanan A, Prabahar K. Real-world functional outcomes of sovateltide as an adjunct to standard therapy in acute ischemic stroke: A prospective observational study. Medicine (Baltimore). 2026 Feb 20;105(8):e47760. doi: 10.1097/MD.0000000000047760. PubMed 41731809 ↗
  • Gulati A, Adwani SG, Vijaya P, Agrawal NR, Ramakrishnan TCR, Rai HP, Jain D, Sundarachary NV, Pandian JD, Sardana V, Sharma M, Sidhu GK, Anand SS, Vibha D, Aralikatte S, Khurana D, Joshi D, Karadan U, Siddiqui MSI. Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial. Drugs. 2024 Dec;84(12):1637-1650. doi: 10.1007/s40265-024-02121-5. Epub 2024 Nov 15. PubMed 39542995 ↗
  • Moustakas D, Mani I, Pouliakis A, Iacovidou N, Xanthos T. The Effects of IRL-1620 in Post-ischemic Brain Injury: A Systematic Review and Meta-analysis of Experimental Studies. Neurocrit Care. 2024 Oct;41(2):665-680. doi: 10.1007/s12028-024-01994-4. Epub 2024 May 9. PubMed 38724864 ↗
  • Mavridis T, Mavridi A, Karampela E, Galanos A, Gkiokas G, Iacovidou N, Xanthos T. Sovateltide (ILR-1620) Improves Motor Function and Reduces Hyperalgesia in a Rat Model of Spinal Cord Injury. Neurocrit Care. 2024 Oct;41(2):455-468. doi: 10.1007/s12028-024-01950-2. Epub 2024 Mar 5. PubMed 38443708 ↗
  • Ranjan AK, Gulati A. Advances in Therapies to Treat Neonatal Hypoxic-Ischemic Encephalopathy. J Clin Med. 2023 Oct 20;12(20):6653. doi: 10.3390/jcm12206653. PubMed 37892791 ↗
  • Keam SJ. Sovateltide: First Approval. Drugs. 2023 Sep;83(13):1239-1244. doi: 10.1007/s40265-023-01922-4. PubMed 37486545 ↗
  • Ranjan AK, Gulati A. Sovateltide Mediated Endothelin B Receptors Agonism and Curbing Neurological Disorders. Int J Mol Sci. 2022 Mar 15;23(6):3146. doi: 10.3390/ijms23063146. PubMed 35328566 ↗
  • Ramos MD, Briyal S, Prazad P, Gulati A. Neuroprotective Effect of Sovateltide (IRL 1620, PMZ 1620) in a Neonatal Rat Model of Hypoxic-Ischemic Encephalopathy. Neuroscience. 2022 Jan 1;480:194-202. doi: 10.1016/j.neuroscience.2021.11.027. Epub 2021 Nov 23. PubMed 34826534 ↗
  • Gulati A, Agrawal N, Vibha D, Misra UK, Paul B, Jain D, Pandian J, Borgohain R. Safety and Efficacy of Sovateltide (IRL-1620) in a Multicenter Randomized Controlled Clinical Trial in Patients with Acute Cerebral Ischemic Stroke. CNS Drugs. 2021 Jan;35(1):85-104. doi: 10.1007/s40263-020-00783-9. Epub 2021 Jan 11. PubMed 33428177 ↗
  • Ranjan AK, Briyal S, Gulati A. Sovateltide (IRL-1620) activates neuronal differentiation and prevents mitochondrial dysfunction in adult mammalian brains following stroke. Sci Rep. 2020 Jul 29;10(1):12737. doi: 10.1038/s41598-020-69673-w. PubMed 32728189 ↗
  • Ranjan AK, Briyal S, Khandekar D, Gulati A. Sovateltide (IRL-1620) affects neuronal progenitors and prevents cerebral tissue damage after ischemic stroke. Can J Physiol Pharmacol. 2020 Sep;98(9):659-666. doi: 10.1139/cjpp-2020-0164. Epub 2020 Jun 23. PubMed 32574518 ↗
  • Gulati A, Hornick MG, Briyal S, Lavhale MS. A novel neuroregenerative approach using ET(B) receptor agonist, IRL-1620, to treat CNS disorders. Physiol Res. 2018 Jun 27;67(Suppl 1):S95-S113. doi: 10.33549/physiolres.933859. PubMed 29947531 ↗
  • Leonard MG, Gulati A. Endothelin B receptor agonist, IRL-1620, enhances angiogenesis and neurogenesis following cerebral ischemia in rats. Brain Res. 2013 Aug 28;1528:28-41. doi: 10.1016/j.brainres.2013.07.002. Epub 2013 Jul 11. PubMed 23850649 ↗
  • Leonard MG, Briyal S, Gulati A. Endothelin B receptor agonist, IRL-1620, provides long-term neuroprotection in cerebral ischemia in rats. Brain Res. 2012 Jun 29;1464:14-23. doi: 10.1016/j.brainres.2012.05.005. Epub 2012 May 9. PubMed 22580085 ↗
  • Leonard MG, Briyal S, Gulati A. Endothelin B receptor agonist, IRL-1620, reduces neurological damage following permanent middle cerebral artery occlusion in rats. Brain Res. 2011 Oct 28;1420:48-58. doi: 10.1016/j.brainres.2011.08.075. Epub 2011 Sep 7. PubMed 21959172 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Feb 2028, 14 months later.

Of 30 phase 3 interventional studies under Brain Injuries, Traumatic, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 69. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 6, 2026
StartEst.
Dec 2026
Primary completionEst.
Feb 2028
CompletionEst.
Mar 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 edited
What changed in the outcomes
  • EditedProportion of patients achieving a favorable functional outcome (GOS-E score ≥7) at Day 90 post-randomization. Score range: 1 to 8; higher scores represent a better outcome.Time frame: 90 days
Oct 13, 2026
Secondary outcomes
4 edited
What changed in the outcomes
  • EditedProportion of patients achieving a favorable functional outcome (GOS-E score ≥7) at Day 180 post-randomization. Score range: 1 to 8; higher scores represent a better outcome.Time frame: 180 days
  • EditedProportion of patients achieving a favorable functional outcome (GOS-E score ≥7) at DaysDay 30 post-randomization. Score range: 1 to 8; higher scores represent a better outcome.Time frame: 30 days
  • EditedProportion of patients with an improvement in Disability Rating Scale (DRS) to less than or equal to 3 at Days 30, 90, and 180 post randomization. Score range: 0 to 30; higher scores represent a worse outcome.Time frame: 180 days
  • EditedChange in the Montreal Cognitive Assessment (MoCA) at Days 30, 90, and 180 post-randomization. Score range: 0 to 30; higher scores represent a better outcome.Time frame: 180 days
Oct 13, 2026
Title
Phase 3 Evaluation of Sovateltide for the Treatment of Acute Traumatic Brain Injury
Oct 13, 2026
Registered
First appeared on the registry
Oct 6, 2026
Show all 2 updates
  1. Oct 13, 2026
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedProportion of patients achieving a favorable functional outcome (GOS-E score ≥7) at Day 90 post-randomization. Score range: 1 to 8; higher scores represent a better outcome.Time frame: 90 days
    Secondary outcomes 4 edited
    What changed in the outcomes
    • EditedProportion of patients achieving a favorable functional outcome (GOS-E score ≥7) at Day 180 post-randomization. Score range: 1 to 8; higher scores represent a better outcome.Time frame: 180 days
    • EditedProportion of patients achieving a favorable functional outcome (GOS-E score ≥7) at DaysDay 30 post-randomization. Score range: 1 to 8; higher scores represent a better outcome.Time frame: 30 days
    • EditedProportion of patients with an improvement in Disability Rating Scale (DRS) to less than or equal to 3 at Days 30, 90, and 180 post randomization. Score range: 0 to 30; higher scores represent a worse outcome.Time frame: 180 days
    • EditedChange in the Montreal Cognitive Assessment (MoCA) at Days 30, 90, and 180 post-randomization. Score range: 0 to 30; higher scores represent a better outcome.Time frame: 180 days
    Title Phase 3 Evaluation of Sovateltide for the Treatment of Acute Traumatic Brain Injury
    + 2 other changes: verification date and description
  2. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07861126
Lead sponsor
Pharmazz, Inc.
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Dec 2026 (estimated)
Primary completion
Feb 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Anil Gulati
Contact
anil.gulati@pharmazz.com
6307806087

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sovateltide

Start the discussion